Abstract
Since the introduction of vaccination in the current COVID-19 outbreak, many countries have approved and implemented vaccination campaigns to mitigate and ultimately curtail the pandemic. Several types of vaccines have been proposed and many of them have finally been approved and used in different countries. The different types of vaccines have different vaccine parameters, and therefore, this situation induces the necessity of modeling mathematically the scenario of multiple imperfect vaccines. In this paper, we introduce a SIR-based model considering different vaccines, and study the basic properties of the model, including the stability of the Disease-Free Equilibrium (DFE), which is locally asymptotically stable if the reproduction number is less than 1. A sequence of further results aims to enumerate the conditions where the reproduction number can be decreased (or increased). Two important mathematical propositions indicate that in general vaccination might not be enough to contain an outbreak and that the addition of new vaccines could be counterproductive if the leakiness parameter is greater than a threshold η. This model, despite its simplicity, was validated with data of the COVID-19 pandemic in five countries: Israel, Chile, Germany, Lithuania, and Czech Republic, observing that improvements for the vaccine campaigns can be suggested by the developed theory.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Ugo Avila Ponce de León is a doctoral student from Programa de Doctorado en Ciencias Biológicas of the Universidad Nacional Autónoma de México (UNAM). This paper was devoloped in the period of his PhD studies. Avila Ponce de León also received a fellowship (CVU: 774988) from Consejo Nacional de Ciencia y Tecnología (CONACYT). In addition, this work was supported in part by Universidad Autónoma de Yucatan and Mexican CONACYT under SNI grant numbers 15284.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB approval was not required since the work used only publicly available data.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data was collected from two different sources: Records from reported recovered and cumulative infected were taken from the John Hopkins repository [link 1] and for vaccination data, we used the repository of Our World in Data [link 2], including the datasets of vaccines per country and vaccines by the manufacturer.
https://github.com/CSSEGISandData/COVID-19
https://github.com/owid/covid-19-data/tree/master/public/data/vaccinations
